Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03786796 · ClinicalTrials.gov registry record · Phase 2

Study of Olaparib in Metastatic Renal Cell Carcinoma Patients With DNA Repair Gene Mutations

A Phase 2 study of Renal Cell Carcinoma and Kidney Cancer, sponsored by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins.

Recruiting
Registry status
Phase 2
Development phase
20
Enrollment target
1
Study location

NCT03786796 is a Phase 2 study of Renal Cell Carcinoma and Kidney Cancer that is actively recruiting participants, run by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins. The registered enrollment target is 20 participants, below the 243-participant average among 121 other Renal Cell Carcinoma trials with a reported enrollment target (92% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03786796, a Phase 2 study of Renal Cell Carcinoma and Kidney Cancer, is actively recruiting participants, sponsored by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins.

RECRUITING
Registry status
Phase 2
Development phase
20 participants
Enrollment target
1
Study location

Study Summary

Single arm, single site, open-label Phase II study of the effects of oral olaparib in participants with metastatic renal cell carcinoma that harbor an inactivating mutation in BAP-1, ATM, BRCA1, BRCA2, PALB2, CHEK2, BRIP1, RAD51C, BARD1, CDK12, CHEK1, FANCL, PP2R2A, RAD51B, RAD51D, or RAD54L who have had prior treatment with at least one immune checkpoint inhibitor or anti-VEGF therapy. Must have measurable disease on CT imaging per RECIST 1.1 criteria.

Conditions Studied

Renal Cell Carcinoma Kidney Cancer Metastatic Renal Cell Carcinoma Renal Carcinoma Kidney Cancer Metastatic

Interventions

  • DRUG Olaparib

Study Locations (1)

Maryland

  • Johns Hopkins Sidney Kimmel Comprehensive Cancer Center - Baltimore

Trial Details

FieldValue
Enrollment Target 20 participants
Start Date 2019-06-03
Est. Completion 2028-03
Phase Phase 2

Sponsor

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

523 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT03786796

The ClinicalTrials.gov registry entry for NCT03786796 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 243-participant average among 121 other Renal Cell Carcinoma trials with a reported enrollment target (92% lower). The listed sponsor is Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, which has 523 total studies on file at ClinicalTrials.gov.

The record links to 5 conditions, with Renal Cell Carcinoma appearing as the primary indexed condition, and to 1 intervention - of which Olaparib is the first listed.

NCT03786796 reports 1 study location spanning 1 distinct geographic area - top geographies include Maryland.

Frequently Asked Questions

What is clinical trial NCT03786796 about?

NCT03786796 is a clinical study titled "Study of Olaparib in Metastatic Renal Cell Carcinoma Patients With DNA Repair Gene Mutations". Single arm, single site, open-label Phase II study of the effects of oral olaparib in participants with metastatic renal cell carcinoma that harbor an inactivating mutation in BAP-1, ATM, BRCA1, BRCA2, PALB2, CHEK2, BRIP1, RAD51C, BARD1, CDK12, CHEK1, FANCL, PP2R2A, RAD51B, RAD51D, or RAD54L who hav...

What is the current status of trial NCT03786796?

This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 20 participants. The study started on 2019-06-03. Estimated completion is 2028-03.

What conditions does trial NCT03786796 study?

This clinical trial studies the following conditions: Renal Cell Carcinoma, Kidney Cancer, Metastatic Renal Cell Carcinoma, Renal Carcinoma, Kidney Cancer Metastatic.

What interventions are being tested in trial NCT03786796?

The interventions under investigation include: Olaparib (DRUG).

Who is sponsoring clinical trial NCT03786796?

This trial is sponsored by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, which has 523 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT03786796 being conducted?

This trial has 1 study location across Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Renal Cell Carcinoma

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Renal Cell Carcinoma

All registered trials for this condition

Kidney Cancer

All registered trials for this condition

Maryland

All trials with a study site in Maryland

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.